Omacetaxine in Gleevec-resistant CML therapy continues to impress

chemo treatment NCI.jpg

According to the results of a small study presented at the American Society of Hematology meeting this weekend, omacetaxine, the investigational drug under development by ChemGenex Pharmaceuticals Limited to treat patients with T315I-positive chronic myeloid leukemia, continues to improve upon its safety profile and efficacy.

Although Gleevec is first-line therapy for chronic myeloid leukemia, some patients have a genetic mutation (T315I) that makes them Gleevec-resistant. Researchers at ChemGenex believe that omacetaxine holds great promise for these patients.

Although currently only used to treat leukemia in China and not approved in Europe or the US, the FDA recently fast-tracked omacetaxine.

Presented as an abstract, until published in a peer-reviewed journal the conclusions of this study are considered preliminary only.

By Ross Bonander

LymphomaInfo Social